AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00249964 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination Treatment - Cohort 1
Description: Paclitaxel at 175 mg/m2 intravenously + Carboplatin at AUC 5 intravenously on day 1.~Temozolomide at 75 mg/m2 per day from day 2 to day 6.
Study NCT00249964 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination Treatment - Cohort 2
Description: Paclitaxel at 175 mg/m2 intravenously + Carboplatin at AUC 5 intravenously on day 1.~Temozolomide at 100 mg/m2 per day from day 2 to day 6.
Study NCT00249964 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination Treatment - Cohort 3
Description: Paclitaxel at 175 mg/m2 intravenously + Carboplatin at AUC 5 intravenously on day 1.~Temozolomide at 125 mg/m2 per day from day 2 to day 6.
Study NCT00249964 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination Treatment - Cohort 4
Description: Paclitaxel at 175 mg/m2 intravenously + Carboplatin at AUC 5 intravenously on day 1.~Temozolomide at 150 mg/m2 per day from day 2 to day 6.
Study NCT03460808 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atorvastatin
Description: Atorvastatin was used in combination with acetylcysteine and danazol.
Study NCT03460808 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetylcysteine
Description: Acetylcysteine was used in combination with atorvastatin and danazol.
Study NCT03460808 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Danazol
Description: Danazol was used in combination with atorvastatin and acetylcysteine or as the monotherapy
Study NCT01840410 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Description: Ranibizumab 0.5mg/0.5mL was administered intravitreally to the participant.
Study NCT01840410 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham control
Description: The sham vial did not contain active drug (empty sterile vial). The sham injection was an imitation of an intravitreal injection using an injection syringe without a needle touching the eye.
Study NCT04515433 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gamma tACS (40 Hz) over the superior parietal cortex
Description: Single session of gamma tACS (40 Hz) over the superior parietal cortex
Study NCT04515433 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Gamma tACS (40 Hz) over the superior parietal cortex
Description: Single session of gamma tACS (40 Hz) over the superior parietal cortex
Study NCT02390453 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Combined Cognitive and Physical
Description: Combined modules provide Cognitive training from Posit Science designed to improve information processing speed, learning, memory, and attention, and Physical training focused on seated aerobic and progressive resistance exercises designed to improve aerobic capacity, muscular strength, and endurance consistent with current exercise recommendations for older adults.
Study NCT02390453 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive
Description: Cognitive modules from Posit Science are designed to improve information processing speed, learning, memory, and attention.
Study NCT02390453 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical
Description: Physical modules are focused on seated aerobic and progressive resistance training designed to improve aerobic capacity, muscular strength, and endurance consistent with current exercise recommendations for older adults.
Study NCT02390453 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active Control
Description: Control modules provide social contact for group discussion of health and successful aging.
Study NCT03921853 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral
Description: The 20-week RT program will consist of three sessions per week, each lasting for 1 hour that will be applied to both control obese (CG) and morbid obese (MO) group. All sessions will start with 15 minutes warm-up with continuous walking and joint mobility and flexibility exercises, 5 minutes of cool down and stretching, in order for preventing injuries. Sessions will include 4 to 8 RT exercises targeting different muscle groups; 1. forearm, 2. knee flexors and 3. extensors, 3. trunk, 4. chest, 5. shoulder elevators, 6. horizontal shoulder flexors and 7. extensors, and 8. plantar flexors. The exercises for each muscle group will be performed in 3 sets of as many repetitions (continuous concentric/eccentric voluntary contraction) possible in 1 minute followed by 2.0 minutes of passive recovery. Before the RT program, each participant will be measure using the subjective modified Borg scale (1-10 points), in order of identifying the muscle failure into 1 minute of exercise.
Study NCT03921853 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Behavioral
Description: The 20-week RT program will consist of three sessions per week, each lasting for 1 hour that will be applied to both control obese (CG) and morbid obese (MO) group. All sessions will start with 15 minutes warm-up with continuous walking and joint mobility and flexibility exercises, 5 minutes of cool down and stretching, in order for preventing injuries. Sessions will include 4 to 8 RT exercises targeting different muscle groups; 1. forearm, 2. knee flexors and 3. extensors, 3. trunk, 4. chest, 5. shoulder elevators, 6. horizontal shoulder flexors and 7. extensors, and 8. plantar flexors. The exercises for each muscle group will be performed in 3 sets of as many repetitions (continuous concentric/eccentric voluntary contraction) possible in 1 minute followed by 2.0 minutes of passive recovery. Before the RT program, each participant will be measure using the subjective modified Borg scale (1-10 points), in order of identifying the muscle failure into 1 minute of exercise.
Study NCT02130323 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imiquimod
Description: 12.5mg (5%) once a week vaginally for 16 weeks
Study NCT02130323 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Loop Electrosurgical Excision Procedure
Description: Patients with CIN 2-3 will be randomized to receive intervention, CKC or LEEP versus medical therapy with Imiquimod.
Study NCT03617900 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ginger
Description: Ginger extract is contains 100 mg/capsules. Use 2 capsules 3 times/day
Study NCT03617900 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Lactose monohydrate 400 mg/capsules
Study NCT03617900 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol
Description: 500 mg paracetamol. use in need
Study NCT03617900 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol
Description: 500 mg paracetamol. use in need
Study NCT03617900 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Paracetamol
Description: 500 mg paracetamol. use in need
Study NCT02879526 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C-CPT
Description: Chidamide 30mg ，twice a week Prednisone 20mg qd Cyclophosphamide 50mg qd Thalidomide 100mg qd
Study NCT04255472 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: WHO Caregiver skills training (CST) program
Description: Caregivers are provided with tangible strategies to appropriately respond to their children's emotional regulation, engagement, and communication. Further, the program focuses on helping caregivers to develop their children's communication and adaptive skills while reducing challenging behavior by focusing on identifying the function of the behavior and learning to teach developmentally appropriate replacement skills. The WHO CST program includes nine group sessions delivered at a community venue (e.g., BHU, school, home) and three home visits: the first at entry prior to session 1, the second after session 4, and the third after the final group session. Training for program facilitators will be included prior to the delivery of the intervention.
Study NCT02463513 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo comparator
Description: 2 week placebo washout + 16 weeks intervention (placebo)
Study NCT02463513 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 1.6mg riboflavin (Vitamin B2)
Description: 2 week placebo washout + 16 weeks intervention (1.6mg riboflavin per day)
Study NCT02463513 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 10mg riboflavin (Vitamin B2)
Description: 2 week placebo washout + 16 weeks intervention (10mg riboflavin per day)
Study NCT02537756 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Project Voice
Description: A tablet-based intervention that directs participants through different activities related to adolescent HPV vaccination based on their assigned condition
Study NCT02918162 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab dosed IV at 200mg every 21 days per cycle.
Study NCT02918162 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of care chemotherapy regimen
Description: Standard regimen containing at least a platinum and Fluorouracil (5-FU) agent (per National Comprehensive Cancer Network guidelines) - such as Doublet or Triplet chemotherapy with capecitabine, oxaliplatin, and epirubicin (optional) (21 day cycle). Epirubicin can be excluded at the discretion of the treating physician.~Example:~Oxaliplatin dosed IV at 130 mg/m2 every 21 days per cycle. Capecitabine dosed orally at 625mg/m2 twice a day daily.
Study NCT04238520 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Functionally Tailored Oral Care Intervention
Description: Participants receive a 4-week, hands-on, functionally-tailored intervention. The intervention will address topics including tooth brushing, denture care, inter-dental care, tongue care, and dry mouth care. There will be four sessions in total, with each intervention session lasting approximately 45 minutes.
Study NCT04238520 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Control Intervention
Description: Participants will receive a home-based, un-tailored oral care training. The training includes a tooth brushing and dental care demonstration, and information about oral diseases and dry mouth. This training will be 15 minutes in duration. Participants will have the opportunity to participate in the functionally tailored intervention following the end of this study.
Study NCT03363295 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin Injection
Description: One group will receive moxifloxacin injection (0,03ml) in the anterior chamber by the end of phacoemulsification surgery
Study NCT04255472 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treatment as usual
Description: WHO CST will be compared with TAU. TAU in primary healthcare centers for childhood developmental disorders and delays usually consists of no treatment, or a range of alternate treatment regimes, such as multi-vitamin syrups and tablets. Evidence-based mental health care is currently not available in primary healthcare centers. A complete record of services availed by the trial participants at tertiary mental healthcare center will be maintained by using an adapted Client Services Receipt Inventory (CSRI) for children with developmental disorders and delays at baseline and end point.
Study NCT03911934 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Polypharmacy intervention
Description: A physician from the Department of Clinical Pharmacology prepares a critial medication review before the first visit in the outpatient clinic through critical review of the patient's medical journal and communication with the patient's GP. During the visit in the outpatient clinic, medications are changed based on the medication review with consent from the patient. After the visit the GP is notified of the changes. It is possible to see the patient more than one time in the outpatient clinic (might be needed if tapering or lots of changes) and possible to follow-up on medication changes by telephone with the patient.
Study NCT03409757 — intervention group
Intervention type: DRUG
Intervention: Velphoro
Description: 4 weeks
Study NCT03409757 — intervention group
Intervention type: OTHER
Intervention: saliva collection
Description: 2 samples
Study NCT03409757 — intervention group
Intervention type: OTHER
Intervention: Supragingival biofilm collection
Description: 2 samples
Study NCT03409757 — intervention group
Intervention type: OTHER
Intervention: stool collection
Description: 2 samples
Study NCT03409757 — intervention group
Intervention type: OTHER
Intervention: blood collection
Description: 2 samples
Study NCT01604681 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 6 capsules per day, thirty minutes before lunch and dinner, eating 3 capsules (3 g) at a time.
Study NCT01604681 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Flaxseed Oil
Description: 6 capsules per day, thirty minutes before lunch and dinner, eating 3 capsules (3 g) at a time.
Study NCT03688230 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: abituzumab
Description: 1000 mg IV
Study NCT03688230 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo + Cetuximab + FOLFIRI
Description: 400 mg/m2 over 120 min followed by 250 mg/m2 weekly 60 min or 500 mg/m2 every two weeks, initially 120 min followed by 60 to 90 min
Study NCT00780520 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: alanine-glutamine infusion
Study NCT00780520 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: alanine-glutamine infusion
Study NCT03911934 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Usual care in the geriatric outpatient clinic with geriatric assessment from a trained geriatrician
Study NCT03911934 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual care
Description: Usual care in the geriatric outpatient clinic with geriatric assessment from a trained geriatrician
Study NCT02986009 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parenting
Description: The parenting intervention consists of four weekly sessions, each lasting two hours. The intervention was designed according to the parenting characteristics of Chinese parents in Hong Kong. The four sessions cover: 1) response modification (stop and rest), 2) relaxation/enhancing positive moods (relax and play), 3) cognitive reframing (think), and 4) using social support (talk and share). Discussion, practice, and questions are involved in each session.
Study NCT02986009 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Information
Description: The information intervention consists of four weekly sessions, each lasting for two hours. The contents cover information and resources about education, medical care, housing, employment, and community facilities available in Hong Kong and Mainland China.
Study NCT02295709 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SNR steroid (dexamethasone) injection
Description: deliver steroids (dexamethasone) into spinal nerve root with the guidance of ultrasound.~Device: Ultrasound (S-Nerve; SonoSite, Bothell, Wash), Probe 9L (6 MHz, SonoSite, Bothell, Wash)
Study NCT02295709 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CTF steroid (dexamethasone) injection
Description: deliver steroids (dexamethasone) into spinal epidural space with the guidance of ultrasound.~Device: Ultrasound (S-Nerve; SonoSite, Bothell, Wash), Probe 9L (6 MHz, SonoSite, Bothell, Wash)
Study NCT02295709 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: One of the most efficient steroids
Study NCT02295709 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: Ultrasound (S-Nerve; SonoSite, Bothell, Wash), Probe 9L (6 MHz, SonoSite, Bothell, Wash)
Study NCT02295709 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: C arm
Description: the needle position will be re-confirmed by C arm C arm (Philips Healthcare, Best, the Netherlands）
Study NCT04165720 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Online questionnaire
Description: Online questionnaire via SoSciSurvey
Study NCT03726463 — intervention group
Intervention type: PROCEDURE
Intervention: Kidney transplantation
Description: Bilateral nephrectomy of polycystic kidneys are routinely performed during kidney transplantation in ADPKD patients
Study NCT03849599 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PRV-300
Description: Treatment
Study NCT03849599 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Control
Study NCT01206842 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training in Affect Recognition
Description: A 12-session social cognitive training programming covering emotion perception and social perception administered in a group setting to up to four participants with schizophrenia at the time
Study NCT02806921 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ZenLens
Description: The ZenLens™ semi-scleral lenses are manufactured by Alden Optic Laboratories Inc., Lancaster, NY. They will be made in Boston XO material.
Study NCT00761592 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum Toxin Type A 900kDa
Description: 6 to 16 injections, with maximum of 21, at a dose of ≥20U/eye (≥40U total dose)
Study NCT00761592 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum Toxin Type A 150kDa
Description: 6 to 16 injections, with a maximum of 21, at a dose of ≥20U/eye (≥40U total dose)
Study NCT00218179 — intervention group
Intervention type: OTHER
Intervention: Non-intervention
Description: Measured total NNAL and PheT as biomarkers of exposure
Study NCT00922779 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2a [Pegasys]
Description: 180micrograms sc weekly for 12-48 weeks
Study NCT00922779 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribavirin
Description: 800mg, or 1000-1200mg, po daily (dependent on HCV genotype and body weight)
Study NCT02627027 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duvie Tab. 0.5mg, Glucodaun OR Tab. 750mg
Description: oral administration
Study NCT02627027 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-395 0.25/750mg
Description: oral administration
Study NCT04138459 — intervention group
Intervention type: OTHER
Intervention: Not an interventional study. This is a qualitative, explorative study of recovery orientation of community mental health services
Description: Explore recovery orientation of mental health services in a municipality through:~1. Qualitative, in-depth interviews with service users and mental health professionals and~2. Observational fieldwork
Study NCT01977092 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational interviewing case management
Study NCT01977092 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Resource referrals
Study NCT01784042 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study NCT01784042 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lovaza
Study NCT01784042 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary energy restriction
Study NCT01784042 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Dietary energy restriction
Study NCT03198013 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: Specified dose on specified days
Study NCT03198013 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-791826
Description: Specified dose on specified days
Study NCT03198013 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Specified dose on specified days
Study NCT00817622 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: EPA, Vitamin E
Description: EPA pearls, 500 mg QID for 12 Weeks (2000 mg per day) Vitamin E pearls, 400 mg per day for 12 weeks
Study NCT00817622 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: EPA, Vitamin E
Description: EPA pearls, 500 mg QID for 12 Weeks (2000 mg per day) Vitamin E pearls, 400 mg per day for 12 weeks
Study NCT05390008 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pelvic Floor Muscle Training
Description: In order to increase participants' PFM strength and endurance , PFMT was taught two days a week for 12 weeks. This training included two type of exercises that consisted of fast and slow PFM contractions.~Fast Contractions: This exercise was done in sitting position, While participants' arms were on thighs with their feet resting on the floor and sitting unsupported on the back of their seat. They were taught how to quickly contract and relax their PFM.~Slow Contractions: The practice position of this exercise was in sitting position as it happened in fast contraction. This training lasted for 12 weeks and it was divided into periods as 1-3 week, 4-6 week, 7-9 week, 10-12 week. In the forth coming weeks of this period, the number of exercise repetitions and the number of sets were increased.